黑色素瘤的辅助干扰素治疗：高剂量、低剂量、不使用剂量，究竟该用哪种剂量？ - Suppr

Suppr

超能文献

Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

作者信息

Schuchter Lynn M

出版信息

J Clin Oncol. 2004 Jan 1;22(1):7-10. doi: 10.1200/JCO.2004.10.907. Epub 2003 Dec 9.

DOI:10.1200/JCO.2004.10.907

PMID:14665612

Abstract

摘要

相似文献

Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

J Clin Oncol. 2004 Jan 1;22(1):7-10. doi: 10.1200/JCO.2004.10.907. Epub 2003 Dec 9.

Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.

J Clin Oncol. 2004 Jan 1;22(1):11-4. doi: 10.1200/JCO.2004.10.952. Epub 2003 Dec 9.

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

J Clin Oncol. 2004 Jan 1;22(1):53-61. doi: 10.1200/JCO.2004.03.185. Epub 2003 Dec 9.

Adjuvant therapy for malignant melanoma.

Expert Rev Anticancer Ther. 2004 Oct;4(5):823-35. doi: 10.1586/14737140.4.5.823.

Adjuvant interferon therapy for melanoma.

J Clin Oncol. 2005 Apr 1;23(10):2431; author reply 2431-2. doi: 10.1200/JCO.2005.99.260.

Current management of melanoma: benefits of surgical staging and adjuvant therapy.

J Surg Oncol. 2003 Mar;82(3):209-16. doi: 10.1002/jso.10216.

Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.

Forum (Genova). 2003;13(2):127-40; quiz 187-8.

[Adjuvant interferon treatment of melanoma].

Magy Onkol. 2003;47(1):105-7. Epub 2003 Apr 18.

The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.

J Am Acad Dermatol. 2000 Oct;43(4):708-11. doi: 10.1067/mjd.2000.107500.

Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.

J Clin Oncol. 2009 Sep 1;27(25):e82-3; author reply e84. doi: 10.1200/JCO.2009.23.0334. Epub 2009 Jul 27.

引用本文的文献

Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care.

Cancers (Basel). 2024 Mar 14;16(6):1151. doi: 10.3390/cancers16061151.

Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies.

Cancers (Basel). 2022 Nov 28;14(23):5858. doi: 10.3390/cancers14235858.

Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities.

Ann Transl Med. 2021 Mar;9(5):423. doi: 10.21037/atm-20-7361.

Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.

Melanoma Manag. 2019 Oct 4;6(4):MMT33. doi: 10.2217/mmt-2019-0015.

IFN-γ: A cytokine at the right time, is in the right place.

Semin Immunol. 2019 Jun;43:101280. doi: 10.1016/j.smim.2019.05.002. Epub 2019 Jun 17.

Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations.

P T. 2017 Jul;42(7):452-463.

Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy.

Oncogene. 2015 Nov 12;34(46):5739-48. doi: 10.1038/onc.2015.22. Epub 2015 Mar 2.

Recent advances in sunlight-induced carcinogenesis using the Xiphophorus melanoma model.

Comp Biochem Physiol C Toxicol Pharmacol. 2012 Jan;155(1):64-70. doi: 10.1016/j.cbpc.2011.03.007. Epub 2011 Mar 30.

A multimarker prognostic assay for primary cutaneous melanoma.

Clin Cancer Res. 2009 Nov 15;15(22):6987-92. doi: 10.1158/1078-0432.CCR-09-1777. Epub 2009 Nov 3.

Antitumor immunity and cancer stem cells.

Ann N Y Acad Sci. 2009 Sep;1176:154-69. doi: 10.1111/j.1749-6632.2009.04568.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验